Townsend & Associates
PFE icon

Townsend & Associates’s Pfizer PFE Stock Holding History

Townsend & Associates’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$269K Buy
9,087
+94
+1% +$2.5K 0.02% 96
2026
Q2 		$223K Buy
8,993
+4
+0% +$105 0.02% 109
2026
Q1 		$241K Buy
8,989
+3
+0% +$80 0.02% 108
2025
Q4 		$233K Buy
8,986
+202
+2% +$5.09K 0.02% 105
2025
Q3 		$215K Sell
8,784
-87
-1% -$2.15K 0.02% 107
2025
Q2 		$220K Sell
8,871
-1,001
-10% -$23.3K 0.02% 99
2025
Q1 		$218K Sell
9,872
-338
-3% -$8.84K 0.02% 94
2024
Q4 		$272K Hold
10,210
– – 0.03% 94
2024
Q3 		$295K Buy
10,210
+404
+4% +$11.8K 0.03% 89
2024
Q2 		$302K Buy
9,806
+6
+0.1% +$165 0.03% 87
2024
Q1 		$258K Buy
9,800
+5
+0.1% +$139 0.03% 88
2023
Q4 		$277K Sell
9,795
-209
-2% -$6.32K 0.03% 89
2023
Q3 		$301K Sell
10,004
-10,092
-50% -$357K 0.06% 86
2023
Q2 		$745K Sell
20,096
-396
-2% -$15.4K 0.19% 85
2023
Q1 		$797K Sell
20,492
-27,261
-57% -$1.18M 0.32% 78
2022
Q4 		$2.1M Sell
47,753
-457
-0.9% -$21.9K 1.04% 36
2022
Q3 		$2.28M Buy
48,210
+6,685
+16% +$325K 1.05% 31
2022
Q2 		$2.2M Buy
+41,525
New +$2.12M 1.02% 25
2021
Q1 		– Sell
-36,128
Closed -$1.33M – 84
2020
Q4 		$1.33M Sell
36,128
-4,362
-11% -$160K 0.97% 52
2020
Q3 		$1.41M Sell
40,490
-13,026
-24% -$457K 1.11% 46
2020
Q2 		$1.66M Sell
53,516
-6,642
-11% -$226K 1.39% 29
2020
Q1 		$1.92M Buy
60,158
+166
+0.3% +$5.66K 1.99% 10
2019
Q4 		$2.22M Sell
59,992
-2,510
-4% -$89.4K 1.94% 10
2019
Q3 		$2.1M Buy
62,502
+12,919
+26% +$470K 2.01% 11
2019
Q2 		$2.09M Buy
49,583
+301
+0.6% +$12K 1.59% 19
2019
Q1 		$1.99M Buy
+49,282
New +$1.97M 2% 21
2018
Q4 		– Sell
-284
Closed -$12K – 126
2018
Q3 		$12K Buy
284
+3
+1% +$115 0.01% 129
2018
Q2 		$10K Sell
281
-131
-32% -$4.48K 0.01% 129
2018
Q1 		$14K Sell
412
-44,059
-99% -$1.51M 0.01% 124
2017
Q4 		$1.53M Buy
+44,471
New +$1.52M 1.3% 27

Other funds holding PFE

Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Pzena Investment Management
Pzena Investment Management New York $34.1B AUM 26.62% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Artemis Investment Management
Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Townsend & Associates's PFE Position: Q3 2026 in Review

Townsend & Associates increased its Pfizer (PFE) stake by 1% in Q3 2026, buying an estimated $2.5K and bringing the position to 9,087 shares worth $269K. The position accounts for 0.02% of the portfolio, ranked #96.

Townsend & Associates first reported a position in PFE in Q4 2017 and has held it in 30 quarters since. The position peaked at $2.28M in Q3 2022. 1,268 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • Townsend & Associates held 9,087 shares of Pfizer worth $269K as of Q3 2026.
  • Townsend & Associates bought 94 Pfizer shares in Q3 2026, an estimated $2.5K.
  • Pfizer made up 0.02% of Townsend & Associates's portfolio in Q3 2026, its #96 holding.
  • Townsend & Associates first reported a position in Pfizer in Q4 2017 and has held it in 30 quarters since.
  • Townsend & Associates's Pfizer position peaked at $2.28M in Q3 2022.
  • 1,268 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on Townsend & Associates's 13F filing for Q3 2026, filed 23 Oct 2026.